Business Context and Reporting Period
This Form 8-K Current Report is filed by NanoVibronix, Inc. (trading symbol: NAOV) on June 4, 2025. The report discloses a significant change in executive leadership effective as of the filing date. The registrant is incorporated in Delaware and its principal executive offices are located in Tyler, Texas.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
- CEO Appointment: The Board of Directors appointed Doron Besser, M.D. as Chief Executive Officer (CEO), effective June 4, 2025. Dr. Besser was previously a director of the Board and the CEO/President of the Company's wholly-owned subsidiary, ENvue Medical Holdings LLC.
- CEO Resignation: Brian Murphy resigned as CEO due to retirement, effective June 4, 2025. Mr. Murphy will remain a director of the Board.
- Executive Background: Dr. Besser brings experience as the former CEO of Angioslide Ltd. and VP roles at superDimension (acquired by Covidien for approximately $300 million in 2012).
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or specific risk factors beyond the standard disclosure of executive transition. The Company expects Dr. Besser to enter into the Company's standard indemnification agreement for officers and an employment agreement, though these documents were not included in this specific filing.
Investor Verification Checklist
- Verify the terms of the new employment agreement for Dr. Besser, which is expected to be filed separately.
- Confirm the strategic rationale for the leadership change in the attached press release (Exhibit 99.1).
- Review upcoming quarterly reports for any impact of the leadership transition on operational strategy.
- Note that the filing references "Envue Medical" in the prompt metadata, but the registrant name in the document is "NanoVibronix, Inc." with a subsidiary named "ENvue Medical Holdings LLC."